28 / 154
xxviii
Contents
COMPREHENSIVE GERIATRICASSESSMENTMAY BE USEFUL ITEMAS PREDICTIVE INDEX OFTREATMENT
COMPLETION FOR ELDERLY PATIENTS WITH LYMPHOMA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S60
SEGA (SHORT EMERGENCY GERIATRIC ASSESSMENT) FRAILTY SCORE IN ELDERLY PATIENTS WITH
HAEMATOLOGICAL MALIGNANCIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S61
A NEW FRAILTY SCORING IN “CLINICALLY FIT” OLDER PATIENTS WITH MALIGNANT HEMOPATHIES
ADMITTED TO RECEIVE CHEMOTHERAPY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S61
EFFECT OF ADEQUATE HYPOMETHYLATING AGENT (HMA) THERAPY ON ADVERSE PROGNOSTIC
FACTORS IN VERY ELDERLY PATIENTS (
75 YRS) WITH MYELODYSPLASTIC SYNDROME (MDS) . . . . . . . . . .S62
FALLS IN OLDER CANCER PATIENTS UNDERGOING SURGERY: PREVALENCE AND ASSOCIATION WITH
GERIATRIC SYNDROMES AND LEVELS OF DISABILITY ASSESSED IN PREOPERATIVE EVALUATION . . . . . . .S62
FRACTURES IN OLDER CANCER PATIENTS, A CALL FOR ACTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S63
NEUROCOGNITIVE PROFILE IN OLDER CANCER PATIENTS IN A GERIATRIC CLINIC . . . . . . . . . . . . . . . . . . . . . . .S63
RESCUE GCS-F USE AS A MARKER OF SAFETY OF ANTI-CANCER TREATMENTS IN GERIATRIC PATIENTS
IN REGIONAL AND RURAL SOUTH AUSTRALIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S64
SARCOPENIA ISASSOCIATEDWITHANUNPLANNED READMISSIONANDWORSE SURVIVAL FOLLOWING
ESOPHAGECTOMY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S65
CLINICAL IMPLICATION OF BODY MASS INDEX, SKELETAL MASS INDEXAND RELATED BLOOD MARKERS
IN THE ELDERLY PATIENTS WITH SOLID TUMORS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S65
THE BEHAVIORAL AND PSYCHOLOGICAL OUTCOMES OF CANCER SURVIVORS: RESULTS FROM THE
IRISH LONGITUDINAL STUDY ON AGEING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S66
ASSESSMENT OF RENAL FUNCTION AMONG PATIENTS WITH BONE METASTASES FROM SOLID TUMORS . . .S67
PROPHYLACTIC USE OF FILGRASTIM TO MANAGE CHEMOTHERAPY-INDUCED NEUTROPENIA IN
ELDERLY PATIENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S67
CHEMOTHERAPY AND HEALTH CARE UTILISATION NEAR THE END OF LIFE IN PATIENTS WITH LUNG
CANCER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S68
MANAGEMENT OF ELDERLY PATIENTS SUFFERING FROMCANCER: ASSESSMENT OF PERCEIVED BURDEN
AND QUALITY OF LIFE OF PRINCIPAL CARER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S69
NEUTROPHIL ENGRAFTMENT AND GRAFT-VERSUS-HOST DISEASE IN ELDERLY PATIENTS UNDERGOING
HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPORTANCE OF BODY COMPOSITION
ASSESSMENT AND GERIATRIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S69
EFFICACY AND SAFETY OF ROLAPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA
AND VOMITING IN PATIENTS AGED <65 VERSUS
65 YEARS RECEIVING MULTIPLE CYCLES OF
EMETOGENIC CHEMOTHERAPY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S70
POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY BREAST AND COLORECTAL CANCER
PATIENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S71
POTENTIAL DRUG INTERACTIONS IN OLDER PATIENTS WITH CANCER: THE ELCAPA COHORT SURVEY
(ELCAPA-15) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S71
APPLICATION OF ADEPT (A PROCESS FOR DECISION-MAKING AFTER PILOT AND FEASIBILITY TRIALS)
TO A PILOT GERIATRIC ONCOLOGY PROGRAMME IN RADIATION THERAPY . . . . . . . . . . . . . . . . . . . . . . . . . .S72
RADICAL RADIOTHERAPY IN PATIENTS AGED OVER 80: A SINGLE UK CENTRE EXPERIENCE . . . . . . . . . . . . . . .S73
HIDDEN PREOPERATIVE GERIATRICS SYNDROMES IN PATIENTS WITH AMERICAN SOCIETY OF
ANESTHESIOLOGISTS CLASS III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S74
THE USE OF DOSE-DENSE WEEKLY PACLITAXEL (WP) CHEMOTHERAPY IN GERIATRIC PATIENTS WITH
GYNAECOLOGICAL CANCERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S75
THE EFFECT OF AGE ON PATIENT REPORTED OUTCOMES FOLLOWING RADICAL PROSTATE RADIOTHERAPYS75
HOW TO ADDRESS THE HETEROGENEITY IN THE DESIGN OF PHASE II CLINICAL TRIALS IN GERIATRIC
ONCOLOGY? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S76
HOME-BASED PREHABILITATION AND REHABILITATION TO OPTIMIZE PHYSICAL FITNESS AND
TREATMENT OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER : A SYSTEMATIC REVIEW S77
ECHOCARDIOGRAPHIC EVALUATION OF CARDIOTOXIC DRUGS IN GERIATRIC CANCER PATIENTS:
BEYOND EJECTION FRACTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S78
PROSPECTIVE COHORT STUDY FROMTHE EORTC (1221-ETF) ONTHE OCCURRENCE OF CANCER EVENTS
IN BELGIAN NURSING HOME RESIDENTS (NHR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S78
CLINICAL BENEFIT RATE AND PARTICIPATION OF PATIENTS WITH ADVANCED CANCER ON PHASE I
CLINICAL TRIALS: A COMPARATIVE ANALYSIS OF SENIOR ADULTS AGED 65 YEARS AND ABOVE
VERSUS MIDDLE AGE AND AYA PATIENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S79
EPIDURAL BASED ANESTHESIA FOR FRAIL ELDERLY PATIENTS IN BREAST CANCER SURGERY: METHOD
OF CHOICE? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S79
MAY THERAPEUTIC DRUG MONITORING OF 5FU DECREASE TOXICITY IN ELDERLY? A RETROSPECTIVE
STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S80
OLDER PATIENTS RECEIVING CHEMOTHERAPY: CHARACTERISING THE POPULATION . . . . . . . . . . . . . . . . . . . .S81
SALVAGE SURGERY OF NON-SMALL CELL LUNG CANCER IN ELDERLY PATIENTSWITH PREVIOUSWEDGE
RESECTION OR LOBECTOMY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S81
EPITOP-01: ELDERLY CANCER PATIENTS, SAFETY AND QUALITY OF LIFE UNDER IMMUNOTHERAPIES: A
PHASE IV TRIAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S82